GSK wins FDA approval for Promacta

11/20/2008 | CNNMoney

GlaxoSmithKline announced that it obtained FDA clearance for Promacta, a treatment for bleeding problems caused by chronic immune thrombocytopenic purpura. Promacta, which was jointly developed with Ligand Pharmaceuticals, should be on the U.S. market by next week, Glaxo said in a statement.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY